Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial

Siobhan Sutcliffe, John F. Alderete, Cathee Till, Phyllis J. Goodman, Ann W. Hsing, Jonathan Mark Zenilman, Angelo Michael Demarzo, Elizabeth A Platz

Research output: Contribution to journalArticle

Abstract

We previously observed a positive association between a history of trichomonosis, a sexually transmitted infection caused by the protozoan, Trichomonas vaginalis, and prostate cancer risk in the Health Professionals Follow-up Study. To determine the reproducibility of this finding, we conducted a second, prospective investigation of trichomonosis and prostate cancer in the Prostate Cancer Prevention Trial. Participants were men (≥55 years of age) with no evidence of prostate cancer at enrollment (n = 18,882). Men were screened annually for prostate cancer, and if not diagnosed during the trial, were offered an end-of-study prostate biopsy. Cases were a sample of men diagnosed with prostate cancer on any biopsy after visit 2 or on their end-of-study biopsy (n = 616). Controls were men not diagnosed with prostate cancer during the trial or on their end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of prostate cancer. Serum from visit 2 was tested for anti-T. vaginalis IgG antibodies. No association was observed between T. vaginalis serostatus and prostate cancer. 21.5% of cases and 24.8% of controls had low seropositivity, and 15.2% and 15.0% had high seropositivity. Compared to seronegative men, the odds ratio of prostate cancer for men with low seropositivity was 0.83 [95% confidence interval (CI): 0.63-1.09), and that for men with high seropositivity was 0.97 (95% CI: 0.70-1.34). Given the original strong biologic rationale and potential for prevention, additional studies are warranted to help resolve discrepancies between study findings and to further investigate this hypothesis from a variety of different approaches.

Original languageEnglish (US)
Pages (from-to)2082-2087
Number of pages6
JournalInternational Journal of Cancer
Volume124
Issue number9
DOIs
StatePublished - May 1 2009

Fingerprint

Prostatic Neoplasms
Biopsy
Trichomonas vaginalis
Confidence Intervals
Sexually Transmitted Diseases
Reproducibility of Results
Prostate
Immunoglobulin G
Odds Ratio
Antibodies
Health
Serum

Keywords

  • Epidemiology
  • Prostate cancer
  • Sexually transmitted infection
  • Trichomonas vaginalis
  • Trichomonosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. / Sutcliffe, Siobhan; Alderete, John F.; Till, Cathee; Goodman, Phyllis J.; Hsing, Ann W.; Zenilman, Jonathan Mark; Demarzo, Angelo Michael; Platz, Elizabeth A.

In: International Journal of Cancer, Vol. 124, No. 9, 01.05.2009, p. 2082-2087.

Research output: Contribution to journalArticle

Sutcliffe, Siobhan ; Alderete, John F. ; Till, Cathee ; Goodman, Phyllis J. ; Hsing, Ann W. ; Zenilman, Jonathan Mark ; Demarzo, Angelo Michael ; Platz, Elizabeth A. / Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. In: International Journal of Cancer. 2009 ; Vol. 124, No. 9. pp. 2082-2087.
@article{77ec9ac88a694ccc999ce256d01f5b08,
title = "Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial",
abstract = "We previously observed a positive association between a history of trichomonosis, a sexually transmitted infection caused by the protozoan, Trichomonas vaginalis, and prostate cancer risk in the Health Professionals Follow-up Study. To determine the reproducibility of this finding, we conducted a second, prospective investigation of trichomonosis and prostate cancer in the Prostate Cancer Prevention Trial. Participants were men (≥55 years of age) with no evidence of prostate cancer at enrollment (n = 18,882). Men were screened annually for prostate cancer, and if not diagnosed during the trial, were offered an end-of-study prostate biopsy. Cases were a sample of men diagnosed with prostate cancer on any biopsy after visit 2 or on their end-of-study biopsy (n = 616). Controls were men not diagnosed with prostate cancer during the trial or on their end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of prostate cancer. Serum from visit 2 was tested for anti-T. vaginalis IgG antibodies. No association was observed between T. vaginalis serostatus and prostate cancer. 21.5{\%} of cases and 24.8{\%} of controls had low seropositivity, and 15.2{\%} and 15.0{\%} had high seropositivity. Compared to seronegative men, the odds ratio of prostate cancer for men with low seropositivity was 0.83 [95{\%} confidence interval (CI): 0.63-1.09), and that for men with high seropositivity was 0.97 (95{\%} CI: 0.70-1.34). Given the original strong biologic rationale and potential for prevention, additional studies are warranted to help resolve discrepancies between study findings and to further investigate this hypothesis from a variety of different approaches.",
keywords = "Epidemiology, Prostate cancer, Sexually transmitted infection, Trichomonas vaginalis, Trichomonosis",
author = "Siobhan Sutcliffe and Alderete, {John F.} and Cathee Till and Goodman, {Phyllis J.} and Hsing, {Ann W.} and Zenilman, {Jonathan Mark} and Demarzo, {Angelo Michael} and Platz, {Elizabeth A}",
year = "2009",
month = "5",
day = "1",
doi = "10.1002/ijc.24144",
language = "English (US)",
volume = "124",
pages = "2082--2087",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial

AU - Sutcliffe, Siobhan

AU - Alderete, John F.

AU - Till, Cathee

AU - Goodman, Phyllis J.

AU - Hsing, Ann W.

AU - Zenilman, Jonathan Mark

AU - Demarzo, Angelo Michael

AU - Platz, Elizabeth A

PY - 2009/5/1

Y1 - 2009/5/1

N2 - We previously observed a positive association between a history of trichomonosis, a sexually transmitted infection caused by the protozoan, Trichomonas vaginalis, and prostate cancer risk in the Health Professionals Follow-up Study. To determine the reproducibility of this finding, we conducted a second, prospective investigation of trichomonosis and prostate cancer in the Prostate Cancer Prevention Trial. Participants were men (≥55 years of age) with no evidence of prostate cancer at enrollment (n = 18,882). Men were screened annually for prostate cancer, and if not diagnosed during the trial, were offered an end-of-study prostate biopsy. Cases were a sample of men diagnosed with prostate cancer on any biopsy after visit 2 or on their end-of-study biopsy (n = 616). Controls were men not diagnosed with prostate cancer during the trial or on their end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of prostate cancer. Serum from visit 2 was tested for anti-T. vaginalis IgG antibodies. No association was observed between T. vaginalis serostatus and prostate cancer. 21.5% of cases and 24.8% of controls had low seropositivity, and 15.2% and 15.0% had high seropositivity. Compared to seronegative men, the odds ratio of prostate cancer for men with low seropositivity was 0.83 [95% confidence interval (CI): 0.63-1.09), and that for men with high seropositivity was 0.97 (95% CI: 0.70-1.34). Given the original strong biologic rationale and potential for prevention, additional studies are warranted to help resolve discrepancies between study findings and to further investigate this hypothesis from a variety of different approaches.

AB - We previously observed a positive association between a history of trichomonosis, a sexually transmitted infection caused by the protozoan, Trichomonas vaginalis, and prostate cancer risk in the Health Professionals Follow-up Study. To determine the reproducibility of this finding, we conducted a second, prospective investigation of trichomonosis and prostate cancer in the Prostate Cancer Prevention Trial. Participants were men (≥55 years of age) with no evidence of prostate cancer at enrollment (n = 18,882). Men were screened annually for prostate cancer, and if not diagnosed during the trial, were offered an end-of-study prostate biopsy. Cases were a sample of men diagnosed with prostate cancer on any biopsy after visit 2 or on their end-of-study biopsy (n = 616). Controls were men not diagnosed with prostate cancer during the trial or on their end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of prostate cancer. Serum from visit 2 was tested for anti-T. vaginalis IgG antibodies. No association was observed between T. vaginalis serostatus and prostate cancer. 21.5% of cases and 24.8% of controls had low seropositivity, and 15.2% and 15.0% had high seropositivity. Compared to seronegative men, the odds ratio of prostate cancer for men with low seropositivity was 0.83 [95% confidence interval (CI): 0.63-1.09), and that for men with high seropositivity was 0.97 (95% CI: 0.70-1.34). Given the original strong biologic rationale and potential for prevention, additional studies are warranted to help resolve discrepancies between study findings and to further investigate this hypothesis from a variety of different approaches.

KW - Epidemiology

KW - Prostate cancer

KW - Sexually transmitted infection

KW - Trichomonas vaginalis

KW - Trichomonosis

UR - http://www.scopus.com/inward/record.url?scp=63449112391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449112391&partnerID=8YFLogxK

U2 - 10.1002/ijc.24144

DO - 10.1002/ijc.24144

M3 - Article

C2 - 19117055

AN - SCOPUS:63449112391

VL - 124

SP - 2082

EP - 2087

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -